Display options
Cite
Cassano G, Petracca A, Borghi C, et al. A randomized, double-blind study of alpidem vs placebo in the prevention and treatment of benzodiazepine withdrawal syndrome. Eur Psychiatry. 1996;11(2):93-9doi: 10.1016/0924-9338(96)84786-9.
Cassano, G., Petracca, A., Borghi, C., Chiroli, S., Didoni, G., & Garreau, M. (1996). A randomized, double-blind study of alpidem vs placebo in the prevention and treatment of benzodiazepine withdrawal syndrome. European psychiatry : the journal of the Association of European Psychiatrists, 11(2), 93-9. https://doi.org/10.1016/0924-9338(96)84786-9
Cassano, G, et al. "A randomized, double-blind study of alpidem vs placebo in the prevention and treatment of benzodiazepine withdrawal syndrome." European psychiatry : the journal of the Association of European Psychiatrists vol. 11,2 (1996): 93-9. doi: https://doi.org/10.1016/0924-9338(96)84786-9
Cassano G, Petracca A, Borghi C, Chiroli S, Didoni G, Garreau M. A randomized, double-blind study of alpidem vs placebo in the prevention and treatment of benzodiazepine withdrawal syndrome. Eur Psychiatry. 1996;11(2):93-9. doi: 10.1016/0924-9338(96)84786-9. PMID: 19698430.
Copy Download .nbib Format: NLM
Share it on

Eur Psychiatry. 1996;11(2):93-9. doi: 10.1016/0924-9338(96)84786-9.

A randomized, double-blind study of alpidem vs placebo in the prevention and treatment of benzodiazepine withdrawal syndrome.

European psychiatry : the journal of the Association of European Psychiatrists

G Cassano, A Petracca, C Borghi, S Chiroli, G Didoni, M Garreau

Affiliations

  1. Clinica Psichiatrica, Università degli Studi di Pisa, Ospedale Santa Chiara, Via Roma 67, 56100 Pisa, France.

PMID: 19698430 DOI: 10.1016/0924-9338(96)84786-9

Abstract

The aim of the trial was to assess alpidem efficacy in preventing and treating the benzodiazepine (BZ) withdrawal syndrome (WS). A multicentre, double-blind, randomized versus placebo, parallel group study of six-week duration was carried out in outpatients suffering from generalized anxiety or adjustment disorder with an anxious mood and taking non-hypnotic BZ as continuous course of therapy of at least one-year duration. At the entry, the patients abruptly discontinued BZs and were treated with 50 mg/bid/tid of alpidem or placebo. Withdrawal syndrome diagnosis was (regarding treatment allocation) formulated by an independent psychiatrist, according to DSM-III-R and an appropriate scale, the SESSB. One hundred seventy-three patients were randomized and 148 completed the study. Withdrawal syndrome occurred in 27 patients of the alpidem group (31.0%) and in 38 patients of the placebo group (44.2%). A severe WS was diagnosed in 11.1% of the patients in the alpidem group and in 31.6% of the placebo group. If not having been withdrawn from the market, alpidem could have been useful for the prevention of BZ withdrawal syndrome.

Publication Types